However, all tumors do not express a significant number of somatostatin type 2 receptors. Therefore, the technique should always be complemented with computed tomography (CT) or magnetic resonance imaging (MRI) depending on the tumor location. PET scanning with specific tracers such as 11 C-5HTP, 18 F-DOPA or 18 F-DG can further optimize the staging of the disease [4] [5] [6] [7] . Endoscopy (gastroscopy, endoscopic ultrasonography, colonoscopy, capsule endoscopy etc.) is often of additional value (III, A). The imaging procedures should always be complemented with biochemical analysis of relevant biomarkers such plasma chromogranin A ( pCgA), which is a general NET marker. In patients with poorly differentiated G3 tumors, pCgA is often normal, but plasma NSE can sometimes be of value as a general marker. For patients with small intestinal NETs (carcinoids), urine 5-hydroxy-indole-aceticacid is important and should be done in combination with the pCgA assessments. For pancreatic NETs, the specific hormones should be analysed in relation to clinical symptoms such gastrin for patients with Zollinger Ellison's syndrome, insulin with hypoglycemic syndromes, glucagon with glucagonoma syndrome and VIP with the Verner Morrison syndrome. Nonfunctioning pancreatic endocrine tumors may secrete increased levels of pCgA as well as pancreatic polypeptide (PP) [8] . Rectal NETs are usually of the so-called nonfunctioning type, but they often secrete hormones, such as PP, somatostatin and PYY. The largest group of GEP-NETs, well differentiated (NETs) of the small intestine (carcinoids), present with the carcinoid syndrome in ∼30% of the patients, including flushing, diarrhea and endocardial fibrosis. The syndrome is caused by serotonin and peptide hormones released from liver metastases but not from the primary small intestinal tumor, as the hormones released to the portal vessels as metabolized in the liver at by-pass (II, A). The 5-year survival rate for patients with midgut carcinoid tumor has been 60% for all stages. In dedicated centers, the 5-year survival rate now for metastatic carcinoid tumors is ∼75%. The 5-year survival rate for patients with endocrine pancreatic tumors is estimated to be 60%-100% for localized disease, 40% for regional and 25% for metastatic and 80% for all stages. Similarly, in dedicated centers, the 5-year survival rate for metastatic pancreatic NETs is above 60% (III, A) [9] [10] [11] [12] .
management of local/locoregional disease
All patients with small intestinal NETs should be considered potential candidates for curative surgery and should be evaluated in an interdisciplinary setting including an In situ tumor/dysplasia (<0.5 mm) T1
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Regional • Gastrinoma, excessive gastrin production, Zollinger-Ellison syndrome • Insulinoma, excessive insulin production, hypoglycemia syndrome • Glucagonoma, excessive glucagons production, glucagonoma syndrome • VIPoma, excessive production of vasoactive intestinal peptide (VIP), Watery diarrhea, hypokalemia-achlorhydria syndrome • PPoma, excessive PP production, (generally classified as nonfunctioning PETs) • Somatostatinoma, excessive somatostatin production • CRHoma, excessive corticotropin-releasing hormones production • Calcitoninoma, excessive calcitonin production • GHRHoma, excessive growth hormone-releasing hormone production • Neurotensinoma, excessive neurotensin production • ACTHoma, excessive production of adrenocorticotropic hormone • GRFoma, excessive production of growth hormone-releasing factor • Parathyroid hormone-related peptide tumor GEP-NETs, neuroendocrine gastroenteropancreatic tumors.
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clinical practice guidelines experienced surgeon. Curative resection of the primary tumor and locoregional lymph node metastases improves outcomes in these patients, resulting in excellent 5-and 10-year survivals of 100% in stage 1 and stage 2 patients, and still favorable outcomes in stage 3 disease with 5-and 10-year survivals of more than 95% and 80%, respectively. Surgical procedures include small intestinal resection or right hemicolectomy depending on the localization of the primary. Curative resection also involves clearance of mesenterial and retroperitoneal lymph node metastases by dissection around the mesentery, preserving the intestinal vascular supply.
Resection of the primary intestinal NET and regional lymph node metastases in patients with distant metastases (liver) is generally advocated to prevent later development of mesenteric fibrosis, small-bowel obstruction or painful vascular encasement. In addition, survival is prolonged in most studies, but survival data are based on retrospective studies, which may have a patient selection bias ( patients with the best performance status are operated). Prospective randomized studies are needed. Large resections of the small intestinal should be avoided as it may cause short-bowel syndrome. Postoperative mortality should be <1% and significant morbidity <10% (II, A). In patients with pancreatic NETs, indications for surgery depend on clinical symptom control, Tumor limited to the pancreas and size ≤2 cm T2
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management of advanced/metastatic disease
Cytoreductive surgery should be considered when metastatic disease is localized or if >70% of tumor load is thought resectable, which may decrease endocrine and local symptoms and might help to improve systemic treatment. There are no randomized clinical trials comparing the efficacy of locoregional therapies and palliative liver surgery [15] . The choice of the ablative or locoregional procedure such as radiofrequency ablation (RFA), laser-induced thermotherapy or selective hepatic transcatheter arterial embolization (TAE), chemoembolization (TACE) and selective internal radiotherapy (SIRT) depends on the local expertise, number and size of lesions and location of liver involvement. These types of locoregional therapies are usually used in combination with systemic medical treatment. If bulky disease is present, locoregional therapy is indicated early also in nonfunctioning tumors and is used for down-staging of the disease. RFAs in tumors <5 cm in size have shown 70%-80% symptomatic responses with control of symptoms up to 1 year (III, B). Selective hepatic TAE or TACE with hepatic artery occlusion can be applied in the treatment of liver metastases from all types of neuroendocrine G1/G2-tumors. Complete or partial response for symptoms, tumor markers and imaging occurred in 70%-100%, 50%-90% and 30%-50% of the patients, respectively. The duration of symptomatic response varied between 14 and 20 months. The procedure is contraindicated in patients with complete portal vein thrombosis and poor liver function. Whipple procedure is also a contraindication for TACE/TAE since it increases the risk of morbidity. In the absence of comparative trials, it remains unclear whether TACE is preferred to TAE alone (III, B). Selective internal irradiation therapy (SIRT) is still considered investigational. Recent studies with 90 Yttrium microspheres in about 200 patients with neuroendocrine tumors show objective response rates of 50%-60% in patients with liver metastases. Most data, however, are retrospective and derive from small phase II trials (III, B). A randomized trial between SIRT and TACE is warranted [16] [17] [18] [19] .
medical therapy
The use of somatostatin analogs is standard therapy in functioning NETs of any size [20, 21] . Interferon alpha may also be considered for symptom control in some patients and is usually used as second line therapy due to its less-favorable toxic profile [22] . It has, sometimes, additional value as an add-on therapy in patients with clinical syndromes that are not controlled with somatostatin analogs. The antitumor efficacy of somatostatin analogs appears weak with respect to objective tumor response (5%-10%). However, disease stabilization of up to 50%-60% has been reported (III, A). In a prospective randomized placebo-controlled trial of octreotide long-acting release (LAR), 30 mg every 4 weeks in small intestinal NET (the PROMID trial), an antiproliferative efficacy of octreotide LAR has been confirmed. The median time to tumor progression was 14.3 months with octreotide LAR versus 6 months with placebo [23] . Based on these results, the use of somatostatin analogs, especially octreotide LAR, is recommended for antiproliferative purposes in functioning and nonfunctioning small intestinal tumors (carcinoids) (II, A). Somatostatin analogs are the recommended first line therapy in nonfunctioning as well as functioning progressive G1/G2 NETs. In contrast, in metastatic NEC G3 regardless of the site of origin somatostatin analog treatment is not recommended (III, B). There is also no indication for adjuvant therapy with somatostatin analogs in NET G1/G2 irrespective of primary tumor origin and potential microscopic metastases (III, B). Other specific therapies in GEP-NETs are the mTOR-inhibitor everolimus, alone or in combination with a somatostatin analog. In the RADIANT-2 trial which was a randomized phase III trial in patients with NETs (carcinoids), everolimus demonstrated a significant antitumor effect compared with placebo by local review but not by central review (I, A). Clinically beneficial effects have been reported in carcinoid patients. In patients with pancreatic NETs, totally 410 patients who were randomized to either everolimus-octreotide or placebo-octreotide, Radiant 3, significant prolonged PFS, 11 versus 4.6 months, was noticed and everolimus is now registered for treatment of pancreatic NETs worldwide (I, A) [24, 25] . Tyrosine kinase inhibitors, sunitinib and pazopanib, have demonstrated significant antitumor efficacy in pancreatic NETs. In a randomized trial, sunitinib (37.5 mg/day) was compared with placebo in 170 patients. The study was Grading proposal for neuroendocrine tumors G1 <2  ≤2  G2  2-20  3-20  G3 >20 >20
Tumor grading and classification. ENETS grading proposal. terminated early due to a significant difference in efficacy between the treatment and the placebo arms. A significant longer PFS, 11 versus 5.5 months was noticed in favor of sunitinib (I, A) [26] . Also sunitinib is now registered worldwide for the treatment of pancreatic NETs. Pazopanib has also demonstrated an antitumor effect in pancreatic NETs in small phase II trials, alone or in combination with octreotide or bevacizumab. Pazopanib may be better tolerated than sunitinib in terms of side-effects.
systemic chemotherapy
Chemotherapy is recommended in NETs, metastatic NET G2 and in NEC G3 of any site. So far, results with systemic chemotherapy in classical carcinoid tumors (G1) are poor with response rates <15% (III, A). Systemic cytotoxics are indicated in patients with inoperable progressive liver metastases from G1/G2 pancreatic NETs using a combination of streptozotocin and 5-fluorouracil (5-FU)/doxorubicin with objective response rates in the order of 35%-40% (II, B). From single retrospective trials, temozolomide-based chemotherapy is promising in pancreatic NETs either alone or combined with capecitabine giving high partial remissions (40%-70%) (III, B). Prospective randomized trials are warranted. In cases of liver metastases involving high-grade NEC G3 regardless of the site of the primary tumor combination chemotherapy, using cisplatinum/etoposide is recommended early. There is no established second-line therapy for poorly differentiated endocrine carcinoma, but recent retrospective studies have demonstrated the efficacy of temozolomide alone or in combination with capecitabine ± bevacizumab (III, B). Encouraging results using either 5-FU i.v. or capecitabine orally combined with oxaliplatin or irinotecan may also be an option in the future (Table 9 ) [27] [28] [29] [30] .
peptide receptor-targeted radiotherapy
Promising data have evolved with regard to peptide receptortargeted radiotherapy (PRRT) in the treatment of NETs with liver metastases using 90 Yttrium and 177 Lutetium labeled DOTATOC or DOTATATE. PRRT can be considered in both functioning and nonfunctioning NETs with positive somatostatin receptor scintigraphy irrespective of the primary tumor site. Based on phase II trials, more than 1000 patients in total have been treated in Europe with objective response rates ranging between 20% and 40% (III, A). Response rates are higher in pancreatic compared with small intestinal NETs (III, A). The highest [31] objective response rate has so far been obtained in metastatic rectal NETs. Prospective randomized trials are still lacking but in progress. A treatment algorithm is depicted in Figure 1 . 
response evaluation and follow-up
Follow-up investigations should include biochemical parameters and conventional imaging. In patients with R0/R1 resected NET G1/G2, it is recommended that imaging is performed every 3-6 months (CT or MRI), and in NEC G3, every 2-3 months. Somatostatin receptor imaging, either Octreoscan or PET/CT using 68 Ga-DOTA-TOC/-NOC/-TATE should be included in the follow-up and is recommended after 18-24 months if expression of somatostatin receptor 2a has been proven on the tumor cells. In the case of rapid tumor progression or if imaging information is lacking, it may be necessary to re-biopsy liver metastases to re-assess the proliferative activity. If chromogranin A is not elevated NSE represents an alternative biomarker.
conflict of interest
Prof. Öberg has reported: speakers' bureau and advisory board membership: Ipsen, Novartis, Pfizer. Prof. Rougier has reported: honoraria from Sanofi Aventis, Amgen, Keocyte, Merck Serono, Pfizer, Roche and Lilly; advisory board for Sanofi Aventis and Keocyte. Dr. Kwekkeboom has not reported any potential conflicts of interests. The other authors have reported no potential conflicts of interest.
references Figure 1 Treatment algorithm. • The current classification and staging systems should be applied in the clinic.
• Somatostatin receptor imaging besides standard imaging (CT and MRI) is part of standard of care.
• Resection of locoregional disease in patients with small intestinal NET (carcinoids) is recommended.
• Somatostatin analog therapy is first-line therapy in all functional NET and small intestinal NET G1/G2.
• Everolimus and sunitinib are registered for pancreatic NETs based on two phase III randomized trials.
• Temozolomide alone or in combination with capecitabine is promising for treatment of pancreatic NETs. 
